Boehringer Ingelheim Signs an Agreement with Invetx to Develop and Commercialize Novel Veterinary Therapies
Shots:
- The companies collaborate to develop novel species-specific mAb biotherapeutics targeting a wide range of diseases in the veterinary species with an initial focus on dogs and cats
- The collaboration will utilize Invetx’s discovery platform- optimization technologies- and Ab expertise to develop veterinary biotherapeutics against selected targets for chronic & serious diseases in animals
- Boehringer Ingelheim will boost veterinary therapies through clinical and regulatory development to the commercialization of the products
| Ref: Boehringer Ingelheim | Image: Franchise India
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].
